June 27, 2025

Also in the News…

The Ophthalmologist brings you the top news stories and studies of the week

The Ophthalmologist

February 26, 2025

Integration of Vision Services Remains an Unmet Need in FQHCs

Telemedicine, funding, and provider partnerships can help, researchers say.

Conexiant

April 02, 2025

GLP-1 RAs Evaluated for Long-Term Risk of NAION in Patients With Diabetes

Researchers’ subgroup analyses provide data on increased risks according to timepoint, demographics, and comorbidities.

Conexiant

November 08, 2024

Is Intravenous Methylprednisolone Efficacious for Visual Complications of GCA?

While timely treatment is essential to protect vision, the researchers found no visual acuity benefit with IVMP.

Conexiant

December 16, 2024

Does Ozempic Double Eye Disease Risk?

Danish health authorities seek EU review of studies linking Novo Nordisk's Ozempic to rare eye condition in type 2 diabetes patients.

Reuters

July 03, 2024

Semaglutide Linked to Vision-Threatening Eye Disorder

New study finds that 8.9% of type 2 diabetes patients taking semaglutide experienced NAION, compared to 1.8% of those on non-GLP-1 diabetes drugs.

Reuters

June 06, 2024

U.S. FDA Halts Biomea's Diabetes Trial

Biomea Fusion announced a clinical hold by the U.S. FDA on its diabetes drug trial due to potential toxic liver disease, causing a 60% drop in its shares.

Reuters

June 10, 2024

Melatonin May Reduce Age-related Macular Degeneration Risk

Melatonin use is associated with a reduced risk of developing and progressing age-related macular degeneration.

Conexiant

January 24, 2025

Once-Weekly Semaglutide Doubles Risk of NAION in T2D

“After the introduction of once-weekly semaglutide in Denmark in November 2018, the annual number of first-time NAION episodes reached an all-time high for the years 2019 through 2023.”

Conexiant